Chimerix Stock

Chimerix FCF Conversion

Delisted·Apr 17, 2025

The FCF Conversion Rate (FCF/EBITDA) of Chimerix (CMRX) as of Aug 26, 2026 is 85.15 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 84.26 % — a change of 1.05% (higher).

FCF Conversion

85.15 %

YoY

1.05%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Chimerix is 2026 85.15 % . FCF Conversion Rate (FCF/EBITDA) of Chimerix was 2025 84.26 % . It decreases by 1.05% higher compared to the previous year.

The Chimerix FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2017
70.83 USD
Jan 1, 2018
77.59 USD
Jan 1, 2019
43.39 USD
Jan 1, 2020
85.69 USD
Jan 1, 2021
39.15 USD
Jan 1, 2022
-27.26 USD
Jan 1, 2023
84.26 USD
Jan 1, 2024
85.15 USD
The Chimerix FCF Conversion history
YEARFCF ConversionYoY
85.15 %+1.05%
84.26 %-409.08%
-27.26 %-169.64%
39.15 %-54.31%
85.69 %+97.50%
43.39 %-44.08%
77.59 %+9.55%
70.83 %-16.32%
84.64 %-2.70%
86.99 %+7.28%
81.09 %
Access this data via the Eulerpool API

Chimerix Stock analysis

What does Chimerix do? Chimerix Inc is a biopharmaceutical company focused on the development of antiviral drugs. The company was founded in 2002 and is headquartered in Durham, North Carolina. The history of Chimerix dates back to the research of Dr. George Painter, a renowned scientist in the field of antiviral therapy. He discovered that a certain group of molecules, known as nucleoside analogues, have antiviral properties. The idea was to use these molecules as a starting point for the development of drugs that specifically target viruses. The core idea of Chimerix was to create a new business model that is different from traditional pharmaceutical companies. Instead of focusing on the lengthy and costly development of new compounds, the company wanted to utilize existing molecules and create new drugs through targeted modifications. This approach was not only expected to be faster and cost-effective but also to offer higher chances of success. Chimerix is divided into several business segments. The most important segment is antiviral therapy, where the company focuses on developing drugs against various viruses such as Cytomegalovirus (CMV), Adenovirus, and Herpesvirus. Another business segment of Chimerix is oncology. Here, the company also relies on modifying existing compounds to develop new and effective cancer drugs. One promising molecule currently being developed is Brincidofovir, which not only has antiviral properties but also possesses antitumor properties. In addition to drug development, Chimerix also offers support for clinical trials. The company collaborates with various research institutions and biopharmaceutical companies to test the efficacy and safety of new compounds. The most well-known product of Chimerix is Brincidofovir. This antiviral drug is currently being tested in clinical trials and has the potential to be used against a range of viruses. Its use is particularly promising in patients undergoing immunosuppressive therapy, such as those after a stem cell transplant. Chimerix aims to develop innovative and effective drugs that help patients overcome serious diseases. With its unique business model and close collaboration with the research community, the company has already made promising progress and is an important player in the field of antiviral therapy and oncology. Chimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Chimerix stock

FCF Conversion Rate (FCF/EBITDA) of Chimerix is 85.15 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Chimerix changed from 84.26 % to 85.15 %, representing a 1.05% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Chimerix since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Chimerix with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Chimerix

All Key Metrics — Chimerix